

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

APR 2 2005
MAILED DATE CANCELLED

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: April 20, 2005 APR 20 2005

(use as many sheets as necessary)

Sheet

1

O I P E

SEARCHED

INDEXED

MAILED

RECORDED

Complete If Known	
Application Number	10/002,634
Filing Date	12/5/2001
First Named Inventor	Anthony E. BOLTON
Group Art Unit	1644
Examiner Name	Belyavskyi, M. A.
Attorney Docket Number	355908-2500

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
M/B	C1	Abbot, et al., Royal Society of Edinburgh Workshop on ME/CIS, "New developments in the biology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" Dundee, UK (October 3, 2003)				
	C2	Natelson et al. "Evidence for the Presence of Immune Dysfunction in Chronic Fatigue Syndrome" <i>Clinical and Diagnostic Immunology</i> 9:747-752 (2002)				
	C3	Patarca-Montero et al. "Immunology of Chronic Fatigue Syndrome" <i>J. of Chronic Fatigue Syndrome</i> 6:69-107				
M/B	C4	Klein et al. "High Incidence of Antibodies to 5-Hydroxytryptamine, Gangliosides and Phospholipids in Patients with Chronic Fatigue and Fibromyalgia Syndrome and their Relatives: Evidence for a Clinical Entity of Both Disorders" <i>Eur J Med Res</i> 1:21-26 (1995/96)				

Examiner Signature		Date Considered	6/29/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.